Full Press Release Details
Viking Therapeutics Presents New Clinical Data on VK2809 in Subjects with Elevated Cholesterol at American Heart Association Scientific Sessions 2016.
VKTX
Viking Therapeutics Presents New Clinical Data on VK2809 in Subjects with Elevated Cholesterol at American Heart Association Scientific Sessions 2016
Key Takeaway: Viking Therapeutics Presents New Clinical Data on VK2809 in Subjects with Elevated Cholesterol at American Heart Association Scientific Sessions 2016
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss